Business Description
Imunon Inc
NAICS : 325412
SIC : 2834
ISIN : US15117N6022
Total Employee Number:
20Description
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 5.26 | |||||
Equity-to-Asset | 0.42 | |||||
Debt-to-Equity | 0.27 | |||||
Debt-to-EBITDA | -0.06 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 51.6 | |||||
3-Year EPS without NRI Growth Rate | 48.8 | |||||
3-Year FCF Growth Rate | 46.1 | |||||
3-Year Book Growth Rate | -65.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 34.36 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.59 | |||||
Quick Ratio | 1.59 | |||||
Cash Ratio | 1.15 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -81.7 | |||||
Shareholder Yield % | -166.66 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -415.59 | |||||
ROA % | -162.89 | |||||
ROIC % | -715.19 | |||||
3-Year ROIIC % | -134.15 | |||||
ROC (Joel Greenblatt) % | -913.37 | |||||
ROCE % | -355.35 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 2.23 | |||||
Price-to-Tangible-Book | 2.22 | |||||
EV-to-EBIT | -0.28 | |||||
EV-to-EBITDA | -0.29 | |||||
EV-to-Forward-Revenue | 39.81 | |||||
EV-to-FCF | -0.28 | |||||
| Price-to-Net-Current-Asset-Value | 3.81 | |||||
| Price-to-Net-Cash | 63.78 | |||||
Earnings Yield (Greenblatt) % | -357.14 | |||||
FCF Yield % | -187.58 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Imunon Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -5.171 | ||
| Beta | 0.7836 | ||
| 3-Year Sharpe Ratio | 0.07 | ||
| 3-Year Sortino Ratio | 0.16 | ||
| Volatility % | 61.45 | ||
| 14-Day RSI | - | ||
| 14-Day ATR ($) | - | ||
| 20-Day SMA ($) | 11.47957 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 11.479565 - 11.47957 | ||
| Shares Outstanding (Mil) | 4.2 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Imunon Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Imunon Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-13 11:00 | In 131 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 130 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 11:00 | In 31 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 | In 30 days | ||
| Life Sciences Virtual Investor Forum | 2026-06-25 12:00 | 11.48 (+0.00%) | ||
| General meeting for 2025 | 2026-06-16 10:00 | 11.48 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-12 11:00 | 11.48 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 11.48 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-31 11:00 | 11.48 (+0.00%) | ||
| Annual report for 2026 | 2026-03-31 | 11.48 (+0.00%) |
Show
Entries
Imunon Inc Frequently Asked Questions
What is Imunon Inc(LTS:0HUZ)'s stock price today?
The current price of LTS:0HUZ is $11.48. The 52 week high of LTS:0HUZ is $11.48 and 52 week low is $11.48.
When is next earnings date of Imunon Inc(LTS:0HUZ)?
The next earnings date of Imunon Inc(LTS:0HUZ) is 2026-08-05 Est..
Does Imunon Inc(LTS:0HUZ) pay dividends? If so, how much?
Imunon Inc(LTS:0HUZ) does not pay dividend.
Press Release
Articles on Imunon Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers